吉林敖东：盐酸纳洛酮注射液通过仿制药质量和疗效一致性评价

Core Viewpoint - The announcement indicates that the company's subsidiary, Yanji Pharmaceutical, has received approval for the "Naloxone Hydrochloride Injection" from the National Medical Products Administration, which is expected to enhance market competitiveness and expand market share, although it is not anticipated to have a significant short-term impact on the company's performance [1] Summary by Relevant Categories Product Approval - Yanji Pharmaceutical has received the approval notice for "Naloxone Hydrochloride Injection" with a specification of 1ml: 0.4mg, under the original drug approval number Guoyao Zhunzi H20066188 [1] Market Impact - The approval allows the product to pass the consistency evaluation of quality and efficacy for generic drugs, which is beneficial for increasing the product's market share and competitiveness [1] - It is expected that there will be no significant impact on the company's performance in the short term [1]